How many employees does ImmuPharma have this year?
ImmuPharma has 17 undefined employees this year.
ImmuPharma Employees 2024
ImmuPharma Employees
17
ImmuPharma Dividend yield
Ticker
IMM.L
ISIN
GB0033711010
WKN
A0BMC4
In 2024, ImmuPharma employed 17 people, a 0% change from the 17 number of employees in the previous year.
ImmuPharma Aktienanalyse
What does ImmuPharma do?
ImmuPharma PLC is a biopharmaceutical company specializing in the development of drugs for the treatment of autoimmune diseases and cancer. The company was founded in 1999 and is headquartered in London, England. ImmuPharma's history began with the discovery of a new peptide extracted from the trail of a snail. This substance has potent immunomodulatory potential and can inhibit the growth of certain tumor cells. ImmuPharma recognized the potential of this discovery and began developing a new drug based on this peptide. ImmuPharma's business model is to develop innovative drugs and license or sell them to large pharmaceutical companies. The company works closely with leading scientists and experts in drug development to ensure the efficacy and safety of its products. ImmuPharma has focused on two main areas: autoimmune diseases and cancer. Autoimmune diseases are conditions in which the immune system malfunctions and attacks the body. The autoimmune diseases that ImmuPharma targets include lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and myasthenia gravis. ImmuPharma has also developed a drug called Lupuzor for the treatment of systemic lupus erythematosus (SLE). SLE is a severe autoimmune disease that causes inflammation and pain in various parts of the body. Lupuzor was developed as a first-in-class drug that regulates the immune system and reduces inflammation without compromising the body's normal defense function. In the field of cancer, ImmuPharma has also developed promising products that aim to inhibit tumor progression. The company has identified and tested a range of peptide- and protein-based drug candidates, including IPP-204106, which is used for the treatment of advanced prostate cancer. Last year, ImmuPharma also developed a new drug called Ureka for the treatment of urinary tract infections. Ureka is a bacterial toxin that specifically targets E. coli bacteria, which are the most common cause of urinary tract infections. In recent years, ImmuPharma has entered into several important partnerships to advance the development of its drugs. One partnership is with the Chinese company Avion Pharmaceuticals, which holds the marketing rights for Lupuzor in North America, Australia, and New Zealand. Another partnership is with the US company Orphan Reach, which supports the development and marketing of Ureka. Overall, ImmuPharma represents innovation and progress in drug development. The company is dedicated to a crucial purpose, seeking cures for those suffering from autoimmune diseases and cancer. Through a combination of scientific excellence and strategic partnerships, ImmuPharma has the potential to achieve significant therapeutic advancements and improve the lives of countless patients. ImmuPharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.Employees Details
Examining ImmuPharma's Employee Base
ImmuPharma's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding ImmuPharma's operational capacity and future potential.
Year-to-Year Comparison
Assessing ImmuPharma's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.
Impact on Investments
ImmuPharma's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.
Interpreting Employee Trends
Fluctuations in ImmuPharma’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.
Frequently Asked Questions about ImmuPharma Stock
How many employees did ImmuPharma have compared to the previous year?
Compared to the previous year, ImmuPharma had 0% more employees.
What impact did the number of employees have on the company ImmuPharma?
The number of employees has a direct impact on the efficiency and productivity of ImmuPharma. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.
What impact did the number of employees have on investors of ImmuPharma?
The number of employees can also have an impact on investors of ImmuPharma, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.
How does an increase in equity capital of ImmuPharma affect the company?
An increase in equity of ImmuPharma can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.
How does a reduction in ImmuPharma's equity affect the company?
A reduction in equity of ImmuPharma can impair its financial stability and decrease its ability to fulfill future investments and obligations.
What are some factors that influence the equity of ImmuPharma?
Some factors that can influence the equity of ImmuPharma include, among others, revenue development, profit and loss statement, dividend payments, and investments.
Why is the equity of ImmuPharma so important for investors?
The equity of ImmuPharma is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.
How does the number of employees at ImmuPharma influence the company?
The number of employees at ImmuPharma can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.
How has the number of employees at ImmuPharma evolved in recent years?
In recent years, the number of employees at ImmuPharma has changed by 0.
How many employees does ImmuPharma currently have?
ImmuPharma currently has 17 undefined employees.
Why is the number of employees important for investors of ImmuPharma?
The number of employees is important for investors of ImmuPharma as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.
What strategic measures can ImmuPharma take to change the number of employees?
To change the number of employees, ImmuPharma can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.
How much dividend does ImmuPharma pay?
Over the past 12 months, ImmuPharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ImmuPharma is expected to pay a dividend of 0 GBP.
What is the dividend yield of ImmuPharma?
The current dividend yield of ImmuPharma is .
When does ImmuPharma pay dividends?
ImmuPharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of ImmuPharma?
ImmuPharma paid dividends every year for the past 0 years.
What is the dividend of ImmuPharma?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is ImmuPharma located?
ImmuPharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von ImmuPharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ImmuPharma from 5/14/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 5/14/2024.
When did ImmuPharma pay the last dividend?
The last dividend was paid out on 5/14/2024.
What was the dividend of ImmuPharma in the year 2023?
In the year 2023, ImmuPharma distributed 0 GBP as dividends.
In which currency does ImmuPharma pay out the dividend?
The dividends of ImmuPharma are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von ImmuPharma
Our stock analysis for ImmuPharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImmuPharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
